MichaelHeifermanMD

Retinal Disease, Ocular Oncology

Assistant Professor of Ophthalmology and Visual Sciences Ophthalmology Residency Associate Program Director

Dr. Heiferman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1009 S. Wood St., 5th Floor
Chicago, IL 60612
Phone+1 312-996-3937

Fax+1 312-996-7770

Dr. Michael Heiferman is an ophthalmologist in Chicago, IL and is affiliated with University of Illinois Hospital & Health Sciences System. He received his medical degree from Northwestern University and has been in practice 4 years. He specializes in retinal disease and ocular oncology. He has more than 20 publications and over 400 citings.

University of Illinois College of Medicine at ChicagoFellowship, Surgical Retina and Vitreous, 2019 - 2021
McGaw Medical Center of Northwestern UniversityResidency, Ophthalmology, 2016 - 2019
Northwestern University The Feinberg School of MedicineClass of 2015

PubMed

Coats disease presenting with vitreous hemorrhage and neovascular glaucoma.
Amrish Selvam, Hesham Gabr, R V Paul Chan, Michael J Heiferman
American Journal of Ophthalmology Case Reports. 2025-03-01
High dynamic range widefield fundus photography with transcranial illumination: a contrast agent-free method for non-mydriatic choroidal imaging.
Mojtaba Rahimi, Alfa Rossi, Taeyoon Son, Tobiloba Adejumo, Albert K Dadzie
Biomedical Optics Express. 2025-01-01
West Nile Retinopathy.
Neil Sheth, Pooja Bhat, Michael J Heiferman
Ophthalmology. Retina. 2025-01-01

Oral Belzutifan Shows Efficacy in Ocular Von Hippel-Lindau DiseaseDecember 5th, 2024
First Liver-Directed Therapy for Metastatic Uveal Melanoma Is ApprovedApril 12th, 2024
Sociodemographic Factors May Be Related to Quality of Ocular Oncology CareJuly 17th, 2024